EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Targeted therapy in recurrent clival chordoma: a case report of response to ivosidenib

Elnaz Rahbarlayegh iD, Santosh Kesari

The Oncologist · 08.07.2026 · 31 (8)

DOI: 10.1093/oncolo/oyag240 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Oncologist, online erschienen am 25.06.2026. Verfasst von Elnaz Rahbarlayegh und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Lundquist Institute, Torrance, CA 90502, United States. Hauptthemen laut MEDLINE: Chordoma, Pyridines, Isocitrate Dehydrogenase, Glycine. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic and molecular alterations in cancer cells can serve as therapeutic targets and enable more precise, individualized treatment strategies. In rare tumors with limited systemic treatment options, molecular profiling may help identify therapeutic opportunities when conventional approaches are exhausted. We report the case of a 72-year-old woman with a long-standing, multiply recurrent clival chordoma and no remaining surgical or radiation options who experienced a meaningful clinical and metabolic response to targeted therapy. Comprehensive tumor molecular profiling identified an activating isocitrate dehydrogenase 1 (IDH1) p. R132C mutation, which guided off-label treatment with the IDH1 inhibitor ivosidenib. Treatment was well tolerated and associated with durable radiographic response with tumor reduction, partial metabolic response on FDG-PET imaging, and clinically significant improvement in neurological symptoms and quality of life. This case highlights the value of molecular tumor board–guided interpretation of genomic alterations and illustrates the potential role of IDH-targeted therapy in select patients with recurrent chordoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChordomaPyridinesIsocitrate DehydrogenaseGlycineNeoplasm Recurrence, LocalSkull Base NeoplasmsHumansFemaleAgedMolecular Targeted TherapyMutation

Stichwörter der Autor:innen

Clival ChordomaIDH1 mutationIvosidenibMolecular tumor boardTargeted Therapy

Substanzen

PyridinesIsocitrate DehydrogenaseivosidenibGlycineIDH1 protein, human

Autor:innen und Institutionen

  • The Lundquist Institute, Torrance, CA 90502, United States.
  • Asthra Health, Santa Monica, CA90404, United States.

ORCID-Profile: Elnaz Rahbarlayegh

Zitieren

APA

Rahbarlayegh, E., & Kesari, S. (2026). Targeted therapy in recurrent clival chordoma: a case report of response to ivosidenib. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag240

Vancouver

Rahbarlayegh E, Kesari S. Targeted therapy in recurrent clival chordoma: a case report of response to ivosidenib. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag240

BibTeX
@article{Rahbarlayegh2026,
  author = {Rahbarlayegh, Elnaz and Kesari, Santosh},
  title = {Targeted therapy in recurrent clival chordoma: a case report of response to ivosidenib},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {8},
  doi = {10.1093/oncolo/oyag240}
}
Kostenlos starten →